-

Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio’s compliance with international standards for medical device quality management systems and reflects the company’s unwavering commitment to excellence, patient safety, and operational rigor.

“This milestone is more than a regulatory requirement—it represents the fulfillment of our promise to stand up a full-scale medical device company,” said Paul Molloy, CEO of Avvio Medical. “Through disciplined execution, a culture of continuous improvement, and a mindset grounded in honor, behavioral integrity, and precision, we have built a foundation for scalable, global operations.” He added, “The quality culture at Avvio is not just a box-checking exercise. We embed it through storytelling, structured messaging, and principles drawn from disciplines of Lean and KAIZEN and a culture Bushidō. As we shared with the BSI audit team, our internal motto is #ImproveEverything—and this certification illustrates that we live by it.”

The ISO 13485 certification now enables Avvio to fully qualify its manufacturing and design processes for commercial scaling, pursue CE marking for international distribution, and reinforce confidence among global partners, investors, and regulators. The achievement is a major step toward the company’s upcoming 2026 commercial launch in the U.S. market. With this certification, Avvio affirms that it is not only compliant—but built to lead.

About the Enhanced Lithotripsy System (ELS)

The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers.

About Avvio Medical

Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company’s system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals.

Contacts

Media Contact:
Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

Avvio Medical, Inc.


Release Versions

Contacts

Media Contact:
Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

More News From Avvio Medical, Inc.

Avvio Medical Announces First Patients Treated with Groundbreaking Kidney Stone Therapy

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc. (formerly Applaud Medical, Inc.) today announced the successful treatment of the first patients using its investigational Enhanced Lithotripsy System (ELS), a pioneering advancement in kidney stone therapy. This milestone follows the company’s recent approval of its Investigational Device Exemption (IDE) by the U.S. Food and Drug Administration (FDA), marking the official launch of its clinical trial. “Our team has developed a world-class solu...

Avvio Medical to Present Clinical Trial Results at the 2025 American Urological Association Annual Meeting

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical Inc. (formerly Applaud Medical, Inc.) today announced that results from its AEROLITH randomized clinical trial will be presented at the upcoming 2025 American Urological Association (AUA) Annual Meeting, taking place April 26-29 in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones....

Applaud Medical Changes Name to Avvio Medical, Ushering in a New Era of Kidney Stone Treatment

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc. (formerly Applaud Medical), a company dedicated to revolutionizing the treatment of urinary stones, today announced a bold step forward with a new name that reflects the Company’s vision for the future. "Avvio is more than just a new name," stated Paul Molloy, President and Chief Executive Officer of Avvio Medical. "Meaning ‘start’, Avvio embodies the company’s unwavering dedication to propelling the future of kidney stone treatment. This name...
Back to Newsroom